- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02817542
Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon (TAHITI)
Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon (STEMI) Patients: 1-year Follow-up of the Prospective Randomised TAHITI Study
Background. Patients with ST-Elevation Myocardial Infarction (STEMI) and hyperglycemia on admission have high rates of mortality (1). The management of hyperglycemic patients during STEMI is unclear. We evaluate whether the thrombus aspiration (TA) before primary percutaneous coronary intervention (PCI) may improve STEMI outcomes in hyperglycemic patients (2).
Research Design and Methods. Consecutive 990 hyperglycemic patients with first STEMI undergoing quantitative coronary angiography were studied. Patients were categorized in two groups, either treated by thrombus aspiration v/s patients treated without thrombus aspiration. After discharge from the hospital, all patients will be managed and followed quarterly for 12 months month after event, as outpatients, to perform clinical evaluation, routine analyses and cardiovascular evaluation. The cardiovascular endpoint collected in both cohorts will include cardiac mortality, all-cause mortality and hospitalization for coronary disease and heart failure.
Conclusions. We will attend improved outcomes in hyperglycemic patients treated by the TA before PCI, as compared to hyperglycemic patients treated only by PCI.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The data analyzed in this study will be obtained from hyperglycemic STEMI patients who underwent primary PCI at the Department of Cardiology of the Cardarelli Hospital in Naples Italy between June 1, 2016, and December 1, 2017. This will be a prospective study to compare two therapeutic strategies: PCI plus thrombus aspiration (TA) versus PCI alone in patients with STEMI and hyperglycemia. According to the recent statement by the American Heart Association, hyperglycemia will be defined as an admission plasma glucose level of >140 mg/dl. Inclusion criteria will include: age of 18 years or greater, presentation to the cardiac catheterization laboratory for PCI in the setting of first STEMI, admission plasma glucose level of >140 mg/dl. All STEMI patients will be referred to the cardiac catheterization laboratory within 12 h of presentation. Patients with left ventricular ejection fraction less than 25%, with previous myocardial infarction or previous PCI or/and coronary by-pass grafting, or had received fibrinolytic therapy will be excluded from the study. The following patients will be referred for urgent invasive diagnostics with the intention of performing PCI: symptom duration of 12 hours or less and ST-segment elevation of 0.1 mV or greater in at least 2 contiguous leads (≥0.2 mV in V1-V3) or presumed new-onset left bundle-branch block. The investigation will be conformed with the principles outlined in the Declaration of Helsinki for use of human tissue or subjects. The Institutional Review Board will approve the protocol.
Outcomes The primary outcome of the THAITI study will be all-cause mortality, cardiovascular deaths, recurrent myocardial infarction, cardiogenic shock, and class IV heart failure within 360 days. Other outcomes will include target vessel revascularisation, stent thrombosis, stroke, and transient ischaemic attack within 360 days.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Naples, Italien, 80100
- Cardarelli Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- age of 18 years or greater, presentation to the cardiac catheterization laboratory for PCI in the setting of first STEMI, admission plasma glucose level ( >140 mg/dl in hyperglycemic Group).
Exclusion Criteria:
- patients with left ventricular ejection fraction less than 25%, with previous myocardial infarction or previous PCI or/and coronary by-pass grafting.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
STEMI TA hyperglycemic subjects
STEMI hyperglycemic patients, percutaneous coronary intervention with TA
|
Percutaneous coronary intervention.
Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion.
A minimum of two syringes (40 mL) of aspirate will be recommended.
The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter.
The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus.
PCI procedure will be done without thrombectomy as per the investigator.
Direct stenting will not be mandated in either treatment group.
Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy.
The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
|
STEMI without TA hyperglycemic subjects
STEMI hyperglycemic patients, percutaneous coronary intervention without TA
|
Percutaneous coronary intervention.
Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion.
A minimum of two syringes (40 mL) of aspirate will be recommended.
The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter.
The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus.
PCI procedure will be done without thrombectomy as per the investigator.
Direct stenting will not be mandated in either treatment group.
Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy.
The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
cardiovascular death
Zeitfenster: 12 months
|
death caused by loss of heart function such as sudden cardiac arrest or heart attack (myocardial infarction).
ECG and cardiac damage markers
|
12 months
|
recurrent myocardial infarction
Zeitfenster: 12 months
|
Myocardial infarction when there is a blockage in one or more of the arteries to the heart, preventing the heart from receiving enough oxygen-rich blood.
If the oxygen in the blood cannot reach the heart muscle, the heart becomes damaged.
ECG and cardiac damage markers
|
12 months
|
heart failure.
Zeitfenster: 12 months
|
Heart failure develops when the heart, via an abnormality of cardiac function (detectable or not), fails to pump blood at a rate commensurate with the requirements of the metabolizing tissues or is able to do so only with an elevated diastolic filling pressure.
ECG and echocardiography
|
12 months
|
acute coronary syndrome
Zeitfenster: 12 months
|
non-ST-elevation acute coronary syndromes (ACSs) and unstable angina.
ECG and cardiac damage markers
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Target vessel revascularisation
Zeitfenster: 12 months
|
Target lesion revascularization was defined as either repeat percutaneous or surgical revascularization for a lesion anywhere within the stent or the 5-mm borders proximal or distal to the stent.
Target lesion revascularization was considered to be ischemia-driven if the target lesion diameter stenosis was ≥50% by quantitative analysis with either electrocardiographic changes at rest or a positive functional study in the distribution of the target lesion, or ≥70% with recurrent symptoms only.
Angiography study
|
12 months
|
stent thrombosis,
Zeitfenster: 12 months
|
Definite or confirmed event with symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of stent thrombosis.Angiography study
|
12 months
|
stroke
Zeitfenster: 12 months
|
The sudden death of brain cells due to lack of oxygen, caused by blockage of blood flow or rupture of an artery to the brain.
Symptoms: Sudden loss of speech, weakness, or paralysis of one side of the body.
CAT scans
|
12 months
|
transient ischaemic attack
Zeitfenster: 12 months
|
.A transient ischemic attack (TIA) is like a stroke, producing similar symptoms, but usually lasting only a few minutes and causing no permanent damage.CAT scans
|
12 months
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Celestino Sardu, MD, PHD, University of Campania "Luigi Vanvitelli"
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Jones DA, Rathod KS, Gallagher S, Jain AK, Kalra SS, Lim P, Crake T, Ozkor M, Rakhit R, Knight CJ, Iqbal MB, Dalby MC, Malik IS, Whitbread M, Mathur A, Redwood S, MacCarthy PA, Weerackody R, Wragg A. Manual Thrombus Aspiration Is Not Associated With Reduced Mortality in Patients Treated With Primary Percutaneous Coronary Intervention: An Observational Study of 10,929 Patients With ST-Segment Elevation Myocardial Infarction From the London Heart Attack Group. JACC Cardiovasc Interv. 2015 Apr 20;8(4):575-84. doi: 10.1016/j.jcin.2014.11.021.
- Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P; American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008 Mar 25;117(12):1610-9. doi: 10.1161/CIRCULATIONAHA.107.188629. Epub 2008 Feb 25. Erratum In: Circulation. 2010 Jun 15;121(23):e444.
- Tilsted HH, Olivecrona GK. To Aspirate or Not to Aspirate: That Is the Question. JACC Cardiovasc Interv. 2015 Apr 20;8(4):585-7. doi: 10.1016/j.jcin.2015.01.014. No abstract available.
- Sardu C, Barbieri M, Balestrieri ML, Siniscalchi M, Paolisso P, Calabro P, Minicucci F, Signoriello G, Portoghese M, Mone P, D'Andrea D, Gragnano F, Bellis A, Mauro C, Paolisso G, Rizzo MR, Marfella R. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol. 2018 Nov 29;17(1):152. doi: 10.1186/s12933-018-0795-8. Erratum In: Cardiovasc Diabetol. 2018 Dec 27;17(1):159.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TAHITI
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur percutaneous coronary intervention
-
Elixir Medical CorporationRekrutierung
-
Elixir Medical CorporationAbgeschlossenKoronare HerzkrankheitNeuseeland, Belgien
-
Elixir Medical CorporationIstituto Clinico HumanitasAktiv, nicht rekrutierendKoronare Herzkrankheit | Chronischer Totalverschluss der Koronararterie | Koronararterienerkrankung mit mehreren Gefäßen | Bifurkation der Koronararterie | Lange Läsionen Koronare HerzkrankheitItalien
-
Elixir Medical CorporationAbgeschlossen
-
Elixir Medical CorporationAbgeschlossenKoronare HerzkrankheitNeuseeland, Belgien, Deutschland, Polen, Dänemark, Brasilien
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.The First Affiliated Hospital of Nanchang University; Shanghai Zhongshan Hospital und andere MitarbeiterRekrutierungChronischer Totalverschluss der KoronararterieChina
-
University of WuerzburgDeutsche Stiftung für HerzforschungUnbekanntStreicheln | Koronare Herzerkrankung | HirninfarktDeutschland
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.RekrutierungKoronararterienperforationChina
-
Shockwave Medical, Inc.AbgeschlossenKoronare HerzkrankheitVereinigtes Königreich, Australien, Frankreich, Niederlande, Schweden
-
Hemolens Diagnostics Sp. z o.o.GENELYTICA Sp. z o.o.AbgeschlossenKoronare Herzkrankheit | Stabile ischämische HerzkrankheitPolen